NFKB1 and neoplasm: Fredrich et al. developed a kind of glycated nanoparticles targeted to myeloid cells, containing three therapeutic payloads to modulate the interaction of TAMs and tumor cells, which targeted the toll-like receptor (TLR), NF-κB, and Janus Kinase (JAK) signaling pathways to drive TAMs towards a distinct anti-tumor phenotype characterized by increased IL-12 production and T cell activation 60.